heterogeneous condition, with at least three genes inautosomal dominant polycystic kidney disease.
PKD2 genes have been recently cloned and character-
Methods. We report a systematic screening for mutations ized [9] [10] [11] [12] [13] . Results. Seven novel mutations were identified and characand complexity (approximately 75% of the gene is dupliterized that, together with the previously described changes, cated). Most of the mutations reported in PKD1 produce amount to a detection rate of 85% in the population studied.
premature translational termination resulting in trun-
The newly described mutations are two nonsense mutations, cated proteins [14] [15] [16] . These truncating mutations suga 1 bp deletion, a 1 bp insertion, a mutation that involves gest that ADPKD is caused by the lack of normal protein.
both a substitution and a deletion (2511AG→C), a complex mutation in exon 6 consisting of a simultaneous 7 bp inversion Furthermore, recent evidence of loss of heterozygosity and a 4 bp deletion, and the last one is a G→C transversion at the PKD1 locus in cystic epithelia has been reported that may be a missense mutation. Most of these mutations are [17, 18] , suggesting that cystogenesis in ADPKD results expected to lead to the formation of shorter truncated proteins from the inactivation of the normal copy of the gene by lacking the carboxyl terminus of PKD2. We have also characterized a frequent polymorphism, Arg-Pro, at codon 28 in this a second somatic mutation. termini and carboxyl termini. There is a 25 to 30% identity and a 45 to 50% similarity between PKD2 and either a 450-amino acid portion of polycystin-1 or a 270 resiAutosomal dominant polycystic kidney disease due region of voltage-activated calcium channel ␣ 1E-1 (ADPKD) is one of the most common Mendelian disor-(VACC␣ 1E-1 ). The cytoplasmic COOH terminal region ders in humans and the most frequent genetic cause of polycystin-2 contains a 29-amino acid segment similar of renal failure in adults [1] . ADPKD is a genetically to an EF-hand domain. Recent evidence suggests that the COOH terminus of PKD2 interacts with the coiled- Currently, several mutations have been described in for mutations in the PKD2 gene. Seven of them were the PKD2 gene, and most of them are expected to profrom Spain (5 from Catalonia and 2 from the center of duce truncated proteins [13, [22] [23] [24] (Table 1) . Here we Spain), and one was from Great Britain. A brief clinical report the identification of seven new mutations in the summary of those in which the mutation was found is PKD2 gene in unrelated Spanish and British families.
shown in Table 2 .
To evaluate the renal survival, the age of family members whose cause of death was uremia was considered, METHODS as well as age of end-stage renal disease (ESRD) for Family description those who died after entering renal replacement therapy. Autosomal dominant polycystic kidney disease diagMutation screening nosis was made according to standard criteria [25] . Link-DNA was prepared from peripheral blood following age studies were performed with PKD1-and PKD2-standard procedures. The 15 coding exons of the PKD2 linked markers to confirm PKD2 gene segregation in all of these families [4, 26, 27]. Eight families were screened gene and the associated splice donor and accepted sites 
Nonsense mutations
Abbreviations are: ESRD, end-stage renal disease; HBP, high blood pressure; N, normal. Two members of family 6138 died with a positive history of intracraTwo nonsense mutations were identified in our samnial aneurysms.
ple. In family C21, a 1249C→T transition that substitutes an arginine for a stop codon at codon 417 (R417X) was identified in exon 5. This mutation creates a novel DdeI restriction site in the sequence. were amplified by polymerase chain reaction (PCR) usThe mutation in family C85 consists of a 1753C→T ing a set of 17 primer pairs described previously [19] .
transition in exon 8 that introduces a stop in codon 585 Exon 1 is amplified in three overlapping PCR products.
(Q585X). This mutation creates a NheI restriction site. Heteroduplex analysis was performed using Hydrolink Mutation Detection Enhancement (MDE) gel solution Mutations causing frameshift (FMC Bioproducts, Rockland, ME, USA) with the addiIn family P326, the disease was shown to be caused tion of 15% (wt/vol) urea, as recommended by the manuby the insertion of one C in a stretch of 6 Cs (nucleotides facturer. Briefly, 20 l of the PCR product were dena-198 to 203). This mutation (198 ins C) is expected to tured by heating at 95ЊC for five minutes, were cooled produce a translation frameshift after codon 68 that inat 37ЊC, and were then loaded. Gels were typically 25 cm troduces 22 novel amino acids before premature terminalong and 1.5 mm thick and were run 10 V/cm, stained with tion. ethidium bromide, and photographed under ultraviolet The mutation in family 6019 consists of a deletion of light.
one A in a stretch of 8 As (nucleotides 2152 to 2159) in exon 11. This deletion (2152 del A) causes a frameshift Automated DNA sequencing and restriction analysis that introduces 15 novel amino acids. Automated sequencing of PCR products was perIn family C113, the sequence of exon 13 revealed a formed on an ABI310 DNA sequencer (Perkin Elmer, mutation involving both substitution and deletion that Norwalk, CT, USA) using the cycle-sequencing method.
affected the dinucleotide AG at position 2511-2 (2511 Sequencing was carried out in both directions with the AG→C). This mutation caused a translation frameshift exon-specific primers. When a deletion or insertion was that introduced six novel amino acids before premature suspected, the PCR product was cloned in pMosBlue termination. This mutation produced the loss of a MboII plasmid vector (Amersham, Arlington Heights, IL, USA) restriction site. to confirm the mutation by sequencing individual bacteIn family 6138, the sequence of exon 6 revealed a rial clones. Restriction analysis was performed according complex mutation comprising both a substitution of a 7 to the manufacturer's instruction.
bp (nucleotides from 1367 to 1373) and a 4 bp deletion (nucleotides 1377 to 1380). The substituted 7 bp stretch Mutation designation was, in fact, an inversion because the sequence matched The mutations described in this study were designated that in the complementary original strand. Closer inspecfollowing the recommendations of Beaudet and Tsui tion of this region showed two pairs of short complemen- [28] . Nucleotides and codons were numbered according tary sequences. The repeats of the first one, of 6 bp, are flanking both the inverted and the deleted sequence, and to the sequence published by Mochizuki et al [13] . the second pair, of 3 bp, flanks the inverted sequence nosis is also higher with fewer renal cysts present at that (Fig. 1) . The 5Ј copies of both pairs are together, whereas time than in PKD1. It is unclear if extrarenal complicathe 3Ј copies are separated by the deleted sequence. It tions of the disease in PKD2 are less severe than in is expected that an intracatenary alignment of this pairs PKD1 [4], but liver cysts seem to occur to the same followed by recombination would simultaneously proextent as in PKD1, and a PKD2 family with intracranial duce the inversion and the deletion. The predicted effect aneurysms has been reported [35] . The clinical features of this mutation is a frameshift from amino acid 456 with of the patients reported here closely resemble those rea premature termination TGA codon after five residues.
ported in previous studies [4, 33] . This mutation produces the loss of a DraI restriction
In the search for PKD2-causing defects in Spanish and site.
English families, we have identified seven novel mutations in exons 1, 4, 5, 6, 8, 11, and 13 of the PKD2 gene.
Missense mutation
Six of them are stop or frameshifting mutations that The only change observed in family C76 was a are expected to produce truncated products lacking the 1066G→C substitution in exon 4 converting Ala356 to carboxyl terminus of PKD2. They are two nonsense muPro (A356P). This transversion creates a StuI restriction tations, a 1 bp deletion, a 1 bp insertion, a change site. To try to determine whether this amino acid change AG→C, and a complex mutation involving both an inveris a disease-causing mutation, another 15 unrelated sion and a deletion in exon 6. This complex mutation PKD2 patients and 100 normal individuals were tested involves exonic sequences that are flanked by short inwith StuI, and no similar change was observed.
verted repeats that might allow the rearrangement to occur by intracatenary recombination. The clinical Polymorphism in exon 1 course of the disease in this family is that of typical Heteroduplex analysis of exon 1 showed a frequent PKD2. Two deceased members exhibited characteristic polymorphism in several PKD2 patients. It consists of a clinical signs and symptoms as a result of intracranial 83G→C transversion converting Arg28 to Pro (R28P).
aneurysms. The expected functional consequence of this This change creates a BanII restriction site. This polymutation is a frameshift translational change with a premorphism was assayed on 15 PKD2 patients and 25 normature termination of protein synthesis. The shortened mal individuals, and a heterozygosity of 0.49 was deproduct would lack the five final transmembrane dotected. There was no difference in the frequency of any mains, as well as the carboxyl terminus. Therefore, no allele between the affected or normal samples. evident relationship could be established between this mutation and the presence of intracranial aneurysms in Survival analysis this family. The survival analysis, estimated through the method
The seventh mutation is a missense mutation that reof Kaplan and Meier, showed a mean survival to ESRD mains to be confirmed as pathogenic. After an extensive of 75.5 years (se Ϯ 3.8 years; data not shown).
study of the proband of this family (C76) by both heteroduplex and single strand conformational polymorphism DISCUSSION (SSCP) analyses, we only found a change in exon 4, where a G is replaced by a C at position 1066. This Mutations in the PKD2 gene are expected to be realteration cosegregates with the disease in the family sponsible for approximately 15% of the cases of polycysand is not present in 100 control individuals. The mutatic kidney disease [3, 4] . The PKD2 disease tends to run tion results in the substitution of a alanine for a proline a milder course than the more common PKD1 [13, 19] , a region tion of a proline at this position may disrupt the secondresponsible for binding of the coiled-coil domain of ary structure of the molecule, resulting in a hampered PKD1, which resides in a fragment spanning the last 97 protein function. The proband of this family entered amino acids of PKD2, and an undefined domain that ESRD at 53 years, an age that can be considered early seems to be implicated in homodimeric interaction with for this disease. It should be noted that in this study, the PKD2 protein itself [20, 21] . The most carboxy termiit has not been determined whether any of the seven nal mutations described so far are in exon 13: 2509G→T mutations are actually stable post-transcriptionally or [24] and 2511AG→C (discussed in this article). post-translationally.
Even though the number of mutations detected in No mutation was found in one family with classic PKD2 patients is increasing, it is not possible at this stage PKD2 and strong familiar evidence of linkage to this to correlate genotype with phenotype. It is imperative to locus. All coding regions have been studied by heteroperform multicentric studies in order to establish if there duplex and SSCA (not shown) analyses in this family, is some kind of correlation between the mutations and and the results suggest that a mutation could lie in the the clinical features of the patients. promoter region, or elsewhere in an intron, or could be due to a large rearrangement. ACKNOWLEDGMENTS In summary, the germinal disease-causing mutation
